3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Cisplatin
136
Cetuximab
101
pembrolizumab
83
Radiotherapy
62
Carboplatin
57
Radiotherapy, Intensity-Modulated
54
Fluorouracil
47
Docetaxel
47
Nivolumab
44
Paclitaxel
37
Radiation
21
Erlotinib Hydrochloride
19
durvalumab
18
Platinum
15
Ipilimumab
14
Gemcitabine
13
lenvatinib
12
Drug Therapy
12
Bevacizumab
12
Albumin-Bound Paclitaxel
12
vandetanib
11
Pemetrexed
11
Magnetic Resonance Spectroscopy
11
1,2-diaminocyclohexaneplatinum II citrate
11
Radiosurgery
10
Everolimus
10
tremelimumab
9
epacadostat
9
Surgical Procedures, Operative
9
Sorafenib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
pralsetinib
×
Head & Neck
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA